New findings from a phase 3 randomized withdrawal trial suggest that continued treatment with ecopipam (Emalex Biosciences), an investigational dopamine D1 receptor antagonist, significantly reduces the risk of symptom relapse in children and adolesc... [4999 chars].. reed more
